Overcoming the shortfalls of ibrutinib with fludarabine in CLL patientss
Common side-effects of BTK inhibitors (ibrutinib and acalabrutinib) in the treatment of CLL
Novel therapies in the future of CLL treatment
Present issues in treating patients with relapsed/refractory CLL
Do immunoglobulin receptor interactions play a role in CLL?